Stock Market & Financial Investment News

News For GSK;PFE From The Last 14 Days Check below for free stories on GSK;PFE the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. << 1 | 2 | all recent news | >> June 19, 2013 16:01 EDT PFE Options Update; June 19, 2013 Subscribe for More Information 10:30 EDT PFE Pfizer management to meet with ISI Group Subscribe for More Information 07:41 EDT PFE Pfizer holders should consider Zoetis exchange, says BMO Capital BMO Capital thinks Pfizer (PFE) investors should consider participating in the Zoetis (ZTS) exchange as they have the opportunity to own Zoetis at around $29.40-$29.70 per share, which is 15% below BMO's valuation of $34 per share. Further, BMO thinks there is strong support for Zoetis below $30, which the firm feels lowers downside risk. BMO recommends that Pfizer investors tender around 20% of their shares into the exchange, noting that with the offer likely being oversubscribed, not all tendered shares will be converted to Zoetis. June 18, 2013 09:38 EDT PFE Active equity option families trading on open Active equity option families trading on open according to Track Data: AAPL NFLX GOOG PFE TSLA MGM 08:37 EDT GSK Drug companies turn to microchips to test medicines, WSJ reports Subscribe for More Information 07:13 EDT GSK Aspen in talks buy GSK's Arixtra, Fraxiparine brands Subscribe for More Information 07:07 EDT GSK GlaxoSmithKline receives offer for thrombosis brands from Aspen GlaxoSmithKline said it received an offer for its thrombosis brands and Notre-Dame de Bondeville site from Aspen Global. A period of exclusivity has been agreed with Aspen. The financial terms are confidential at this time, but the offer includes the transfer of the Arixtra and Fraxiparine brands to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees, GSK said. "The proposed transaction is aligned to GSK's strategy of focusing on products with the most growth potential and the delivery of its pipeline," the company added. June 17, 2013 16:00 EDT PFE Options Update; June 17, 2013 Subscribe for More Information 08:36 EDT PFE InSite Vision to join Merck, Pfizer patent suit against Mylan InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. 07:28 EDT PFE Cambridge Healthtech Institute to host a conference Subscribe for More Information June 14, 2013 16:00 EDT PFE Options Update; June 14, 2013 Subscribe for More Information 06:45 EDT PFE Zoetis volatility elevated into Pfizer split-off Subscribe for More Information June 13, 2013 16:00 EDT PFE Options Update; June 13, 2013 Subscribe for More Information 07:32 EDT PFE European League Against Rheumatism to host annual meeting Subscribe for More Information June 12, 2013 19:54 EDT GSK GlaxoSmithKline investigates bribe claims in China, WSJ says Subscribe for More Information 16:02 EDT PFE Options Update; June 12, 2013 Subscribe for More Information 13:31 EDT PFE Mylan could be interested in generic assets split from Pfizer, Bloomberg says 08:28 EDT PFE Teva to pay $1.6B to settle with Pfizer, Nycomed over generic Protonix Subscribe for More Information 08:02 EDT PFE Pfizer wins $2.15B settlement from Teva and Sun for patent infringement Subscribe for More Information 07:16 EDT GSK GlaxoSmithKline fires head of R&D in China, WSJ says GlaxoSmithKline has fired it's head of R&D in China after finding that he had incorporated "misinterpreted" data in a paper he helped write for a journal, Nature Medicine, according to The Wall Street Journal, citing the company. Reference Link June 11, 2013 16:00 EDT PFE Options Update; June 11, 2013 Subscribe for More Information 15:15 EDT PFE Pfizer June volatility at one-year high Subscribe for More Information 07:42 EDT PFE Boston Biotech Conferences to host a conference Subscribe for More Information June 10, 2013 07:40 EDT PFE Leerink's biotech analyst holds analyst/industry conference call on ASCO Subscribe for More Information 07:20 EDT PFE Biomed to host a conference Subscribe for More Information June 6, 2013 15:59 EDT GSK FDA votes for modified restrictions on GSK's Avandia, Reuters says Subscribe for More Information 15:42 EDT GSK FDA panel revote reaffirms modified restrictions for GSK's Avandia, Reuters says 15:26 EDT GSK FDA advisers say Glaxo Avandia vote may have been inaccurate, Bloomberg says Advisers plan to take a break to assess problem with vote tally and plan to re-vote on GSK's Avandia after break, Bloomberg says. 15:20 EDT GSK FDA panel votes to modify market restrictions for Avandia, Reuters says Subscribe for More Information June 5, 2013 07:45 EDT GSK FDA to host a joint committee meeting Joint Meeting of the Endocrinilogic & Metabolic Drugs Advisory Committee and the Drug Safety & Risk Management Advisory Committee where the discussion on both days will be on GlaxoSmithKline's New Drug Application (NDA) 21071 for AVANDIA (Rosiglitazone Maleate) tablets is being held in FDA Offices in Silver Spring, Maryland on June 5-6 beginning at 8 am. Webcast Link << 1 | 2 | all recent news | >> Sign up for a free trial to see the rest of the stories you've been missing.